BACKGROUND: Alemtuzumab (Campath-1H) induction with tacrolimus monotherapy has been shown to provide effective immunosuppression for kidney, liver, lung, and small bowel transplantation. This drug combination was evaluated in pancreas transplant recipients. METHODS: Sixty consecutive pancreas transplants (30 simultaneous pancreas-kidney, 20 pancreas after kidney, and 10 pancreas alone) were carried out under this protocol between July 2003 to January 2005. The mean follow-up was 22 months (range 17-33). RESULTS: One-year patient, pancreas, and kidney allograft survival were 95%, 93%, and 90%, respectively. With 22 months follow-up, patient, pancreas, and kidney survival were 94%, 89%, and 87%, respectively. The rejection rate was 30% (18/60), with four patients (7%) experiencing steroid-resistant rejection. Major infection occurred in three (5%) patients resulting in two (3.3%) deaths from disseminated histoplasmosis and a herpes virus infection. One patient with cryptococcal meningitis was successfully treated. Seven (11.7%) patients experienced cytomegalovirus infection, all of whom responded to treatment with ganciclovir. One (1.7%) case of polymorphic posttransplant lymphoproliferative disease was seen, which regressed with a temporary discontinuation of tacrolimus and high-dose ganciclovir. The mean serum creatinine of the 30 simultaneous pancreas-kidney transplants at one year posttransplant was 1.37+/-0.33 mg/ml. The preexisting creatinine in pancreas after kidney transplants was not adversely affected by this immunosuppressive protocol. CONCLUSION: A single dose of perioperative alemtuzumab followed by daily tacrolimus monotherapy provides effective immunosuppression for pancreas transplantation, but the optimal use of this drug combination is not yet clear.
BACKGROUND:Alemtuzumab (Campath-1H) induction with tacrolimus monotherapy has been shown to provide effective immunosuppression for kidney, liver, lung, and small bowel transplantation. This drug combination was evaluated in pancreas transplant recipients. METHODS: Sixty consecutive pancreas transplants (30 simultaneous pancreas-kidney, 20 pancreas after kidney, and 10 pancreas alone) were carried out under this protocol between July 2003 to January 2005. The mean follow-up was 22 months (range 17-33). RESULTS: One-year patient, pancreas, and kidney allograft survival were 95%, 93%, and 90%, respectively. With 22 months follow-up, patient, pancreas, and kidney survival were 94%, 89%, and 87%, respectively. The rejection rate was 30% (18/60), with four patients (7%) experiencing steroid-resistant rejection. Major infection occurred in three (5%) patients resulting in two (3.3%) deaths from disseminated histoplasmosis and a herpes virus infection. One patient with cryptococcal meningitis was successfully treated. Seven (11.7%) patients experienced cytomegalovirus infection, all of whom responded to treatment with ganciclovir. One (1.7%) case of polymorphic posttransplant lymphoproliferative disease was seen, which regressed with a temporary discontinuation of tacrolimus and high-dose ganciclovir. The mean serum creatinine of the 30 simultaneous pancreas-kidney transplants at one year posttransplant was 1.37+/-0.33 mg/ml. The preexisting creatinine in pancreas after kidney transplants was not adversely affected by this immunosuppressive protocol. CONCLUSION: A single dose of perioperative alemtuzumab followed by daily tacrolimus monotherapy provides effective immunosuppression for pancreas transplantation, but the optimal use of this drug combination is not yet clear.
Authors: Ngoc L Thai; Kareem Abu-Elmagd; Akhar Khan; Geoffrey Bond; Amit Basu; Kusum Tom; George Mazariegos; Rakesh Sindhi; Jorge Reyes; Henkie P Tan; Amadeo Marcos; Thomas E Starzl; Ron Shapiro Journal: Clin Transpl Date: 2004
Authors: Christopher J E Watson; J Andrew Bradley; Peter J Friend; John Firth; Craig J Taylor; John R Bradley; Kenneth G C Smith; Sathia Thiru; Neville V Jamieson; Geoff Hale; Herman Waldmann; Roy Calne Journal: Am J Transplant Date: 2005-06 Impact factor: 8.086
Authors: Ron Shapiro; Demetrius Ellis; Henkie P Tan; Michael L Moritz; Amit Basu; Abhay N Vats; Akhtar S Khan; Edward A Gray; Adrianna Zeevi; Corde McFeaters; Gerri James; Mary Jo Grosso; Amadeo Marcos; Thomas E Starzl Journal: J Pediatr Date: 2006-06 Impact factor: 4.406
Authors: Andreas G Tzakis; Tomoaki Kato; Seigo Nishida; David M Levi; Juan R Madariaga; Jose R Nery; Naveen Mittal; Arie Regev; Patricia Cantwell; Anthony Gyamfi; Debbie Weppler; Joshua Miller; Panagiotis Tryphonopoulos; Phillip Ruiz Journal: Transplantation Date: 2003-04-27 Impact factor: 4.939
Authors: Amadeo Marcos; Bijan Eghtesad; John J Fung; Paulo Fontes; Kusum Patel; Michael Devera; Wallis Marsh; Timothy Gayowski; Anthony J Demetris; Edward A Gray; Bridget Flynn; Adriana Zeevi; Noriko Murase; Thomas E Starzl Journal: Transplantation Date: 2004-10-15 Impact factor: 4.939
Authors: Jeffrey Rogers; Alan C Farney; Samer Al-Geizawi; Samy S Iskandar; William Doares; Michael D Gautreaux; Lois Hart; Scott Kaczmorski; Amber Reeves-Daniel; Stephanie Winfrey; Mythili Ghanta; Patricia L Adams; Robert J Stratta Journal: Rev Diabet Stud Date: 2011-05-10
Authors: Jeffrey Rogers; Alan C Farney; Giuseppe Orlando; Samy S Iskandar; William Doares; Michael D Gautreaux; Scott Kaczmorski; Amber Reeves-Daniel; Amudha Palanisamy; Robert J Stratta Journal: World J Diabetes Date: 2014-12-15